Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy
Not Applicable
Active, not recruiting
- Conditions
- Fallopian Tube CancerOvarian CancerStage III Ovarian CancerStage IV Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Carcinoma
- Registration Number
- NCT04204811
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Brief Summary
The purpose of this study is evaluate whether a prehabilitation program is feasible and useful for women with advanced ovarian cancer receiving chemotherapy in preparation for debulking surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- Female
- Target Recruitment
- 22
Inclusion Criteria
- Subjects must be diagnosed with Stage III or Stage IV ovarian carcinoma (which includes primary peritoneal carcinoma or fallopian rube carcinoma)
- All subjects must be enrolled within 90 days of diagnosis
- No prior treatment for ovarian carcinoma
- All subjects have agreed to a treatment plan of neoadjuvant chemotherapy and subsequent planned interval debulking surgery with an MSKCC surgeon
- Participants must be initiating treatment at Gynecologic Medical Oncology clinics at MSKCC Manhattan
- Proficiency in English in the determination of the investigators of by patient self-report
Exclusion Criteria
- Patient under age 18
- Prior treatment for ovarian cancer
- Second opinion visit only
- Immediate surgery plan without neoadjuvant treatment
- No intended surgical plan
- Chemotherapy administration exclusively planned at MSKCC regional site
- Patient unwilling to sign consent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Median completion of participants Up to 1 year Study will be considered feasible if the cohort has a median completion of 70% or more
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie prehabilitation care in advanced ovarian cancer patients undergoing neoadjuvant chemotherapy?
How does prehabilitation care compare to standard-of-care approaches in improving outcomes for Stage III/IV ovarian cancer patients?
Which biomarkers could identify ovarian cancer patients most likely to benefit from prehabilitation care before debulking surgery?
What are the potential adverse events associated with prehabilitation programs in advanced ovarian cancer and how are they managed?
Are there combination therapies or pharmaceutical interventions that enhance prehabilitation outcomes in advanced ovarian cancer patients?
Trial Locations
- Locations (1)
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
Memorial Sloan Kettering Cancer Center🇺🇸New York, New York, United States